CORE Diagnostics Launches nephroCORE for Targeting Kidney Disease

By SiliconIndia   |   Wednesday, 23 January 2019, 09:01 Hrs
cmt right
Comment Right
cmt right
cmt right
Printer Print Email Email
CORE Diagnostics Launches nephroC¬¬ORE for Targeting Kidney Disease

To ensure best clinical intervention for improved outcomes in chronic and generic kidney diseases, CORE Diagnostics announces the launch of nephroCORE, new division for advanced diagnostic services in nephrology. One among the few laboratories in India providing expert services, CORE’s new addition –  nephrology diagnostic tests, comprises of advanced nephro-pathology services, molecular testing for rare and inherited (genetic) kidney diseases, screening for pre and post-transplant infectious diseases, monitoring drug levels and Transplant Immunology.  

According to healthcare estimates, kidney disease is the third biggest killer after cancer and cardiac ailments globally. Nearly 200,000 kidney failures occur in India annually with six out of ten patients suffering from kidney disease (CKD), diabetes and hypertension. The prevalence of end-stage renal disease requiring a transplant in India is estimated to be between 151 and 232 per million of the population. Kidney disease has indeed assumed worrisome proportions in India.

The Brain Behind Development

Owning to its high-end diagnostics capabilities, CORE continuously invests resources and talent n identifying and introducing novel diagnostics, which are critical in combating complicated diseases including chronic kidney disease. The company brings ease to clinicians’ lives through real-time data collection done via easy shipping and doorstep sample collection and uses special collection kits only for better sample stability, quality reporting and faster turnaround time.

On the occasion, Zoya Brar, Founder & MD, CORE Diagnostics asserts “Unsuccessful or inadequate clinical intervention impose heavy financial burden on patients. We are confident that with the newest addition of nephrology diagnostic services, we will improve the healthcare outcomes and quality of lives of the patients we serve”. Adding to that, Dr. Rajan Duggal, Vice President nephroCORE says, “Kidney biopsies are the gold-standard for the diagnosis of medical and transplant kidney disorders. At CORE, we run the rarest of high-end diagnostic markers on renal biopsy samples that help us come up with a definitive diagnosis along with prognostic information for the treating physician”.

The vent also marked attendance of Dr. Vijay Kher (Medanta Hospital) who spoke about ‘Renal Biopsy reporting: Expectations of a Nephrologist’, Dr. Dinesh Khullar (Max Hospital, Saket), Dr. P.P Varma (Venkateshwara Hospital), Dr. Manju Aggarwal (Artemis Hospital) and Dr. Saurabh Pokhariyal (Manipal Hospital) who participated in panel discussion on ‘Interesting Renal Biopsies’ moderated by Dr. Vivekanand Jha, President International Society of Nephrology.

Read more news:

B-group vitamins beneficial for psychotic patients: Study

Edutech firm Byju's buys US-based Osmo for $120 mn


Facebook-owned messaging app WhatsApp is still developing its previously announced "Vacatio..
"Game of Thrones" author George R.R. Martin doesn't want season eight to be the final chapter of "..
Startup City
Youth are leading India's start-up ecosystem where the median age of founder-entrepreneurs..
Enterprise IT
Taking on streaming giants like Netflix and Hulu, Walt Disney Co. has announced it will laun..
The Reserve Bank of India injected a total liquidity of Rs 2.98 lakh crore in the market in 20..
Wiley, a global leader in research and education has announced a series of blended learning progr..
US Indian
Facebook-owned photo messaging app Instagram has launched the beta version of its in-app sh..
Google Pixel and OnePlus smartphones are catching up and giving stiff competition to Samsu..
The Pentagon has selected Microsoft and Amazon Web Services (AWS, the cloud computing arm ..